Clinical comparisons of botulinum neurotoxin formulations

Research output: Contribution to journalReview article

26 Scopus citations

Abstract

Background: The expanding uses of botulinum neurotoxin (BoNT) for a growing number of clinical indications, including cervical and other dystonias, adult and childhood spasticity, and hyperhidrosis, in conjunction with the emergence of new formulations of BoNT, prompt discussion of the differences in formulations, serotypes, and indications for different neurologic diseases. Review Summary: This review will evaluate evidence from preclinical studies, prospective treatment studies, and direct comparative trials to discuss the differences among BoNTs and the clinical implications of using these different drugs. Data from these sources indicate that formulations of BoNT are distinct; even the same serotype formulations of BoNT serotype A have different molecular structures and sizes and therapeutic indices (reflected in different safety and efficacy profiles). Conclusion: Taken together, these findings confirm that the different BoNT serotypes, including the different BoNTA formulations, are distinct therapeutic entities.

Original languageEnglish (US)
Pages (from-to)289-298
Number of pages10
JournalNeurologist
Volume14
Issue number5
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

    Fingerprint

Keywords

  • Bioequivalence
  • Blepharospasm
  • Botulinum toxin
  • Cervical dystonia
  • Dose ratio
  • Hemifacal spasm
  • Spasticity, hyperhidrosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this